Darien, Connecticut – July 7, 2026 – United Health Products, Inc. (OTCQB: UEEC) today announced an agreement with NAMSA, the global leader in MedTech contract research offering end-to-end development services, whereby NAMSA will serve as regulatory sponsor of a new clinical study of UHP’s CelluSTAT Hemostatic Gauze.
Consistent with the company’s recent proposal to the FDA to have a non-affiliated party oversee a new clinical study, which the FDA approved in March of this year, NAMSA will initially seek an Investigational Device Exemption (IDE) to organize and conduct a study of UHP’s neutralized cellulose hemostat technology. Upon completion of the study, UHP will hold an exclusive right of reference to all data from the study to use in a revised Premarket Approval (PMA) application. This plan will allow a study to proceed (subject to granting of the IDE) while UHP works with the FDA to resolve the outstanding Warning Letter.
NAMSA is exclusively focused on medical device and in vitro diagnostic technologies. Its experts bring decades of experience in clinical trial management for Class III devices, including hemostatic agents, as well as experience working with the FDA Center for Devices and Radiological Health.
Brian Thom, UHP’s CEO commented, “NAMSA has been a great partner to UHP for several years in our preclinical testing efforts and I am delighted that we are expanding our relationship with such a well-regarded and capable CRO. NAMSA’s deep experience in the clinical study of new medical devices and in working through the FDA approval process give me confidence in their ability to efficiently sponsor and execute a rigorous human study evaluating the safety and effectiveness of our CelluSTAT Hemostatic Gauze.”
About United Health Products — UHP has developed and patented a Neutralized Regenerated Cellulose hemostatic agent. CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding. UHP is seeking approval to access the human surgical market.
For more information on UHP visit the company’s new website: www.uhpcorp.com or contact the company at info@uhpcorp.com.
The company can also be reached by phone or text message at 475.755.1005.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.About NAMSA — Founded in 1967, NAMSA is a global MedTech Contract Research Organization (CRO) offering end-to-end development services across clinical research, regulatory and reimbursement consulting, biocompatibility testing, and preclinical research. With more than 1,500 experts across the U.S., Europe, and Asia-Pacific, NAMSA serves over 3,000 MedTech companies worldwide, from emerging innovators to established global manufacturers. Learn more at namsa.com.